Combination treatment of malignant B cells using the anti-CD20 antibody rituximab and the anti-malarial artesunate.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  International Journal of Oncology

• Publication date

  2009-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3892/IJO_00000323PMID 19513562
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cisplatin induces mitochondrial oxidative stress with resultant energetic metabolism impairment, membrane rigidification and apoptosis in rat liver

  2008cited by this paper
• Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1

  2007cited by this paper
• Role of Transferrin Receptor and the ABC Transporters ABCB6 and ABCB7 for Resistance and Differentiation of Tumor Cells towards Artesunate

  2007cited by this paper
• The NO TRAIL to YES TRAIL in cancer therapy (review).

  2007cited by this paper
• Willmar Schwabe Award 2006: Antiplasmodial and Antitumor Activity of Artemisinin - From Bench to Bedside

  2007cited by this paper
• Artesunate Induces ROS-Mediated Apoptosis in Doxorubicin-Resistant T Leukemia Cells

  2007cited by this paper
• Fas Receptor Clustering and Involvement of the Death Receptor Pathway in Rituximab-Mediated Apoptosis with Concomitant Sensitization of Lymphoma B Cells to Fas-Induced Apoptosis1

  2007cited by this paper
• Microarray expression profiles of angiogenesis-related genes predict tumor cell response to artemisinins

  2006cited by this paper
• Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells.

  2006cited by this paper
• Artesunate in the treatment of metastatic uveal melanoma--first experiences.

  2005cited by this paper
• Mechanistic perspectives for 1,2,4-trioxanes in anti-cancer therapy.

  2005cited by this paper
• Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention

  2005cited by this paper
• Rituximab-Induced Inhibition of YY1 and Bcl-xL Expression in Ramos Non-Hodgkin’s Lymphoma Cell Line via Inhibition of NF-κB Activity: Role of YY1 and Bcl-xL in Fas Resistance and Chemoresistance, Respectively1

  2005cited by this paper
• Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis

  2005cited by this paper
• Glutathione-related enzymes contribute to resistance of tumor cells and low toxicity in normal organs to artesunate.

  2005cited by this paper
• Direct Antilymphoma Effects on Human Lymphoma Cells of Monotherapy and Combination Therapy with CD20 and HLA-DR Antibodies and 90Y-Labeled HLA-DR Antibodies

  2005cited by this paper
• Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774.

  2004cited by this paper
• Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: Pivotal role of p38 MAPK in drug resistance

  2004cited by this paper
• Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate.

  2004cited by this paper
• Non-Hodgkin lymphoma: an update.

  2004cited by this paper
• ROS stress in cancer cells and therapeutic implications.

  2004cited by this paper
• Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron.

  2004cited by this paper
• Role of antioxidant genes for the activity of artesunate against tumor cells.

  2003cited by this paper
• Molecular modes of action of artesunate in tumor cell lines.

  2003cited by this paper
• Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis.

  2003cited by this paper
• Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma.

  2002cited by this paper
• Transcriptional regulation of the human manganese superoxide dismutase gene: the role of specificity protein 1 (Sp1) and activating protein-2 (AP-2).

  2002cited by this paper
• mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether.

  2002cited by this paper
• CD20-induced B cell death can bypass mitochondria and caspase activation

  2002cited by this paper
• Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells.

  2002cited by this paper
• Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.

  2001cited by this paper
• Nitric oxide disrupts H2O2-dependent activation of nuclear factor kappa B. Role in sensitization of human tumor cells to tumor necrosis factor-alpha -induced cytotoxicity.

  2001cited by this paper
• Sp1 and krüppel‐like factor family of transcription factors in cell growth regulation and cancer

  2001cited by this paper
• The anti-malarial artesunate is also active against cancer.

  2001cited by this paper
• Nitric Oxide Disrupts H2O2-dependent Activation of Nuclear Factor κB

  2001cited by this paper
• Regulation of the catalase gene promoter by Sp1, CCAAT-recognizing factors, and a WT1/Egr-related factor in hydrogen peroxide-resistant HP100 cells.

  2001cited by this paper
• Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs.

  2001cited by this paper
• Life and death decisions: regulation of apoptosis by proteolysis of signaling molecules

  2000cited by this paper
• Cytotoxic drugs and the CD95 pathway

  1999cited by this paper
• Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.

  1999cited by this paper
• Activation-Dependent Transcriptional Regulation of the Human fas Promoter Requires NF-κB p50-p65 Recruitment

  1999cited by this paper
• Analysis of the transcriptional activity of the 5′‐flanking region of the rat catalase gene in transiently transfected cells and in transgenic mice

  1998cited by this paper
• Transcriptional Regulation of the 5′ Proximal Promoter of the Human Manganese Superoxide Dismutase Gene

  1998cited by this paper
• Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic Drugs

  1997cited by this paper
• Detection of apoptosis in KG-1a leukemic cells treated with investigational drugs.

  1996cited by this paper
• Molecular Structure and Organization of the Human Manganese Superoxide Dismutase Gene

  1994cited by this paper
• Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

  1994cited by this paper
• A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry.

  1991cited by this paper
• Structure of the human genomic glutathione S-transferase-pi gene.

  1989cited by this paper

• Artemisinin and Its Derivatives from Molecular Mechanisms to Clinical Applications: New Horizons Beyond Antimalarials

  2025cites this paper
• Yin Yang 1 (YY1) as a Central Node in Drug Resistance Pathways: Potential for Combination Strategies in Cancer Therapy

  2025cites this paper
• Formononetin and Dihydroartemisinin Act Synergistically to Induce Apoptosis in Human Acute Myeloid Leukemia Cell Lines

  2024cites this paper
• Malaria as Potential Aetiology and Treatment Complicating Factor in DLBCL Patient: A Case Report

  2023cites this paper
• Is Artesunate the Best Partner of Gemcitabine in Pancreatic Cancer?

  2022cites this paper
• Artemisinin-Type Drugs in Tumor Cell Death: Mechanisms, Combination Treatment with Biologics and Nanoparticle Delivery

  2022cites this paper
• Artesunate induces apoptosis, autophagy and ferroptosis in diffuse large B cell lymphoma cells by impairing STAT3 signaling.

  2021cites this paper
• Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge?

  2021cites this paper
• The immunosuppressive activity of artemisinin‐type drugs towards inflammatory and autoimmune diseases

  2021cites this paper
• Artemisinin-type drugs for the treatment of hematological malignancies

  2020cites this paper
• Therapeutic Potentials and Mechanisms of Artemisinin and its Derivatives for Tumorigenesis and Metastasis.

  2020cites this paper
• Research Progress on Artemisinin and Its Derivatives against Hematological Malignancies

  2020cites this paper
• The combination of artesunate and carboplatin exerts a synergistic anti‐tumour effect on non‐small cell lung cancer

  2020cites this paper
• Artemisia annua, a Traditional Plant Brought to Light

  2020cites this paper
• Effects of Rituximab on JAK-STAT and NF-κB signaling pathways in acute lymphoblastic leukemia and chronic lymphocytic leukemia

  2019cites this paper
• Combination therapies of Artemisinin and its derivatives as a viable approach for future cancer treatment.

  2019cites this paper
• Distinct Activities of Glycolytic Enzymes Identify Chronic Lymphocytic Leukemia Patients with a more Aggressive Course and Resistance to Chemo-Immunotherapy

  2018cites this paper
• Sensitization of tumor cells to chemotherapy by natural products: A systematic review of preclinical data and molecular mechanisms.

  2018cites this paper
• A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies

  2018cites this paper
• Cytotoxicity of Endoperoxides from the Caribbean Sponge Plakortis halichondrioides towards Sensitive and Multidrug-Resistant Leukemia Cells: Acids vs. Esters Activity Evaluation

  2017cites this paper
• Induction of autophagy and autophagy‐dependent apoptosis in diffuse large B‐cell lymphoma by a new antimalarial artemisinin derivative, SM1044

  2017cites this paper
• Cancer combination therapies with artemisinin‐type drugs

  2017cites this paper
• From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapy.

  2017cites this paper
• Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis

  2015cites this paper
• Artesunate induces apoptosis via a ROS-independent and Bax-mediated intrinsic pathway in HepG2 cells.

  2015cites this paper
• Artemisinin–second career as anticancer drug?

  2015cites this paper
• Activation of Mitochondria-Driven Pathways by Artemisinin and Its Derivatives

  2014cites this paper
• Mitochondria: The Anti- cancer Target for the Third Millennium

  2014cites this paper
• The anti-lymphoma activity of APO866, an inhibitor of nicotinamide adenine dinucleotide biosynthesis, is potentialized when used in combination with anti-CD20 antibody

  2014cites this paper
• Rituximab: modes of action, remaining dispute and future perspective.

  2014cites this paper
• Effect of Caspase Inhibitor Ac-DEVD-CHO on Apoptosis of Vascular Smooth Muscle Cells Induced by Artesunate

  2014cites this paper
• Anti-malarial drug artesunate protects against cigarette smoke-induced lung injury in mice.

  2014cites this paper
• Stimulation of Suicidal Erythrocyte Death by Artesunate

  2014cites this paper
• Treatment of Iron-Loaded Veterinary Sarcoma by Artemisia annua

  2014cites this paper
• Activity of Artemisinin-Type Compounds Against Cancer Cells

  2013cites this paper
• The Use of Artemisinin Compounds as Angiogenesis Inhibitors to Treat Cancer

  2013cites this paper
• Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by artesunate

  2013cites this paper
• Development of artemisinin compounds for cancer treatment

  2013cites this paper
• Bioinformatic and experimental fishing for artemisinin-interacting proteins from human nasopharyngeal cancer cells.

  2012cites this paper
• The antimalarial agent artesunate possesses anticancer properties that can be enhanced by combination strategies

  2011cites this paper
• Molecular mechanisms of the antitumor effects of anti-CD20 antibodies.

  2011cites this paper
• 741 EFFECT OF CASPASE INHIBITOR AC-DEVD-CHO ON APOPTOSIS OF VASCULAR SMOOTH MUSCLE CELLS INDUCED BY ARTESUNATE

  2011cites this paper
• Therapeutic and Toxicological Inhibition of Vasculogenesis and Angiogenesis Mediated by Artesunate, a Compound with Both Antimalarial and Anticancer Efficacy

  2011cites this paper
• thnobotanical survey and cytotoxicity testing of plants of South-western igeria used to treat cancer , with isolation of cytotoxic constituents from ajanus cajan Millsp . leaves

  2010cites this paper
• Ethnobotanical survey and cytotoxicity testing of plants of South-western Nigeria used to treat cancer, with isolation of cytotoxic constituents from Cajanus cajan Millsp. leaves.

  2010cites this paper
• Factors determining sensitivity or resistance of tumor cell lines towards artesunate.

  2010cites this paper
• Design of novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties

  2010cites this paper
• Cytotoxicity of artesunic acid homo- and heterodimer molecules toward sensitive and multidrug-resistant CCRF-CEM leukemia cells.

  2010cites this paper
• Effect of artesunate on immune cells in ret-transgenic mouse melanoma model

  2009cites this paper